Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities
Sagun Parakh, Matthias Ernst, Ashleigh R. Poh
Cancers (2021) Vol. 13, Iss. 24, pp. 6228-6228
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Current treatments for non-small cell lung cancer
Qianqian Guo, Liwei Liu, Zelong Chen, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 72
Farnesoid X receptor promotes non-small cell lung cancer metastasis by activating Jak2/STAT3 signaling via transactivation of IL-6ST and IL-6 genes
Xiuye Jin, Bin Shang, Junren Wang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 10
Immunotherapeutic hydrogel for co-delivery of STAT3 siRNA liposomes and lidocaine hydrochloride for postoperative comprehensive management of NSCLC in a single application
Xianglei Fu, Yanbin Shi, Zili Gu, et al.
Asian Journal of Pharmaceutical Sciences (2024) Vol. 19, Iss. 3, pp. 100925-100925
Open Access | Times Cited: 6
Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance
Shigeru Hashimoto, Ari Hashimoto, Ryuta Muromoto, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2618-2618
Open Access | Times Cited: 26
Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
Kostas A. Papavassiliou, Γεώργιος Μαρίνος, Athanasios G. Papavassiliou
Cancers (2023) Vol. 15, Iss. 2, pp. 386-386
Open Access | Times Cited: 14
Insights into the Mechanisms of Action of Proanthocyanidins and Anthocyanins in the Treatment of Nicotine-Induced Non-Small Cell Lung Cancer
Naser A. Alsharairi
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 7905-7905
Open Access | Times Cited: 20
Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions
Ramin Yousefpour Shahrivar, Zahra Ahmadi Fakhr, Elham Abbasgholinejad, et al.
Advanced Therapeutics (2023) Vol. 6, Iss. 12
Closed Access | Times Cited: 12
Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway
Xinglong Ma, Wenyuan Xu, Xinmeng Jin, et al.
European Journal of Pharmacology (2023) Vol. 942, pp. 175529-175529
Closed Access | Times Cited: 11
Exosomal miR-21 determines lung-to-brain metastasis specificity through the DGKB/ERK axis within the tumor microenvironment
Tung-Yu Tiong, M. Ete Chan, Chun‐Hua Wang, et al.
Life Sciences (2023) Vol. 329, pp. 121945-121945
Closed Access | Times Cited: 11
β-elemene: A promising natural compound in lung cancer therapy
Jiguang Bao, Zhiliang Li, D Zhang
European Journal of Pharmacology (2025), pp. 177399-177399
Closed Access
Extracts from Allium pseudojaponicum Makino Target STAT3 Signaling Pathway to Overcome Cisplatin Resistance in Lung Cancer
Soo-Bin Nam, Jung Hoon Choi, Ga-Eun Lee, et al.
Marine Drugs (2025) Vol. 23, Iss. 4, pp. 167-167
Open Access
Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19
Aroona Razzaq, Cyrollah Disoma, Yuzheng Zhou, et al.
Reviews in Medical Virology (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 10
It’s all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma
Rebeca Yakubov, Ramneet Kaloti, Phooja Persaud, et al.
Journal of Neuro-Oncology (2025)
Open Access
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
Kyli Berkley, Julian Zalejski, Ashutosh Sharma
Cancers (2025) Vol. 17, Iss. 5, pp. 755-755
Open Access
Unravelling key signaling pathways for the therapeutic targeting of non-small cell lung cancer
P. Chavan, Ruchi Pandey, BHEEMANAGOUDA O. PATIL, et al.
European Journal of Pharmacology (2025), pp. 177494-177494
Closed Access
STAT3 Signaling Pathway in Health and Disease
Md Abdus Samad, Iftikhar Ahmad, A. M. Mahedi Hasan, et al.
MedComm (2025) Vol. 6, Iss. 4
Open Access
Unraveling the kinase code: Role of protein kinase in lung cancer pathogenesis and therapeutic strategies
Mena Fatma, Sana Parveen, Snober S. Mir
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189309-189309
Closed Access
Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells
Iacopo Gesmundo, Francesca Pedrolli, F.R. Giglioli, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3267-3267
Open Access
Progression and Expansion of ALK Inhibitors Against NSCLC: A Dual Target Approach
Shreya Kumari, Mymoona Akhter, Ghanshyam Das Gupta, et al.
European Journal of Medicinal Chemistry (2025) Vol. 293, pp. 117722-117722
Closed Access
Mebendazole induces apoptosis and inhibits migration via the reactive oxygen species-mediated STAT3 signaling downregulation in non-small cell lung cancer
Zhipan Liang, Qiu‐Yun Chen, Liuying Pan, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 2, pp. 1412-1423
Open Access | Times Cited: 3
MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen
Richard E. Kast, Alex Alfieri, Hazem Assi, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2563-2563
Open Access | Times Cited: 14
The Chemokine CCL4 Stimulates Angiopoietin-2 Expression and Angiogenesis via the MEK/ERK/STAT3 Pathway in Oral Squamous Cell Carcinoma
Chien-Chi Lu, Hsiao‐Chi Tsai, Dong‐Ying Yang, et al.
Biomedicines (2022) Vol. 10, Iss. 7, pp. 1612-1612
Open Access | Times Cited: 14
Nanoparticle-Mediated Delivery of STAT3 Inhibitors in the Treatment of Lung Cancer
Qiyi Feng, Kai Xiao
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2787-2787
Open Access | Times Cited: 14
Modulation of cellular metabolism and alleviation of bacterial dysbiosis by Aconiti Lateralis Radix Praeparata in non-small cell lung cancer treatment
Wen Zhang, Menglei Ding, Yaru Feng, et al.
Phytomedicine (2023) Vol. 126, pp. 155099-155099
Closed Access | Times Cited: 8
Single-Cell Profiling Comparisons of Tumor Microenvironment between Primary Advanced Lung Adenocarcinomas and Brain Metastases and Machine Learning Algorithms in Predicting Immunotherapeutic Responses
Yijun Wu, Kai Kang, Han Chang, et al.
Biomolecules (2023) Vol. 13, Iss. 1, pp. 185-185
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top